These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 4009236)

  • 21. Abrogation of peripheral cholecystokinin-satiety in the capsaicin treated rat.
    MacLean DB
    Regul Pept; 1985 Aug; 11(4):321-33. PubMed ID: 2413505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effects of the cholecystokinin-B receptor antagonist, PD 134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dopamine neuronal activity in the substantia nigra and ventral tegmental area.
    Meltzer LT; Christoffersen CL; Serpa KA; Razmpour A
    Synapse; 1993 Feb; 13(2):117-22. PubMed ID: 8446920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Electrophysiological studies on the specificity of the cholecystokinin antagonist proglumide.
    Chiodo LA; Freeman AS; Bunney BS
    Brain Res; 1987 May; 410(2):205-11. PubMed ID: 3036308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The feeding responses evoked by cholecystokinin are mediated by vagus and splanchnic nerves.
    Brown TA; Washington MC; Metcalf SA; Sayegh AI
    Peptides; 2011 Aug; 32(8):1581-6. PubMed ID: 21745513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lesion of vagal afferent terminals impairs glucagon-induced suppression of food intake.
    Weatherford SC; Ritter S
    Physiol Behav; 1988; 43(5):645-50. PubMed ID: 3200921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of cholecystokinin and caerulein on human eating behavior and pain sensation: a review.
    Stacher G
    Psychoneuroendocrinology; 1986; 11(1):39-48. PubMed ID: 3085129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capsaicin application to central or peripheral vagal fibers attenuates CCK satiety.
    South EH; Ritter RC
    Peptides; 1988; 9(3):601-12. PubMed ID: 3420015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Electrical physiological evidence for highand low-affinity vagal CCK-A receptors.
    Li Y; Zhu J; Owyang C
    Am J Physiol; 1999 Aug; 277(2):G469-77. PubMed ID: 10444462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cholecystokinin-8s excites identified rat pancreatic-projecting vagal motoneurons.
    Wan S; Coleman FH; Travagli RA
    Am J Physiol Gastrointest Liver Physiol; 2007 Aug; 293(2):G484-92. PubMed ID: 17569742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of neurotransmitter release by cholecystokinin in the neostriatum and substantia nigra of the rat: regional and receptor specificity.
    You ZB; Herrera-Marschitz M; Pettersson E; Nylander I; Goiny M; Shou HZ; Kehr J; Godukhin O; Hökfelt T; Terenius L; Ungerstedt U
    Neuroscience; 1996 Oct; 74(3):793-804. PubMed ID: 8884775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of A9 and A10 dopamine cells by the cholecystokinin-B antagonist LY262691: mediation through feedback pathways from forebrain sites.
    Rasmussen K; Howbert JJ; Stockton ME
    Synapse; 1993 Oct; 15(2):95-103. PubMed ID: 8259526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response of the gastric vagal afferent activity to cholecystokinin in rats lacking type A cholecystokinin receptors.
    Kurosawa M; Bucinskaite V; Taniguchi T; Miyasaka K; Funakoshi A; Lundeberg T
    J Auton Nerv Syst; 1999 Jan; 75(1):51-9. PubMed ID: 9935269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of action of peripherally administered cholecystokinin octapeptide on brain stem neurons in the rat.
    Raybould HE; Gayton RJ; Dockray GJ
    J Neurosci; 1988 Aug; 8(8):3018-24. PubMed ID: 3411366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-affinity CCK-A receptors on the vagus nerve mediate CCK-stimulated pancreatic secretion in rats.
    Li Y; Hao Y; Owyang C
    Am J Physiol; 1997 Sep; 273(3 Pt 1):G679-85. PubMed ID: 9316472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vagal afferent-dependent cholecystokinin modulation of visceral pain requires central amygdala NMDA-NR2B receptors in rats.
    Wang EM; Li WT; Yan XJ; Chen X; Liu Q; Feng CC; Cao ZJ; Fang JY; Chen SL
    Neurogastroenterol Motil; 2015 Sep; 27(9):1333-43. PubMed ID: 26197883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paraventricular nucleus lesions abolish the inhibition of feeding induced by systemic cholecystokinin.
    Crawley JN; Kiss JZ
    Peptides; 1985; 6(5):927-35. PubMed ID: 4080609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Inhibitory effect of substance P of caudate nucleus on gastric motility via substantia nigra and dorsal vagal nucleus mediated by vagus nerve].
    Jing H; Zhang J; Lin KW
    Sheng Li Xue Bao; 1996 Jun; 48(3):269-76. PubMed ID: 9389185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electrophysiological effects of cholecystokinin: central dopaminergic systems.
    Wang RY; White FJ
    Prog Clin Biol Res; 1985; 192():95-103. PubMed ID: 4080721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experimental spinal cord injury in rats diminishes vagally-mediated gastric responses to cholecystokinin-8s.
    Tong M; Qualls-Creekmore E; Browning KN; Travagli RA; Holmes GM
    Neurogastroenterol Motil; 2011 Feb; 23(2):e69-79. PubMed ID: 20950355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Peptides of digestive system and brain. Model of the cholecystokinin].
    Gibbs J; Smith GP
    Ann Endocrinol (Paris); 1988; 49(2):113-20. PubMed ID: 3048188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.